Related Experiment Videos
Immunohistochemical analysis of RCAS1 in human pituitary adenomas
Abstract:
It has been reported that RCAS1 (receptor-binding cancer antigen expressed on SiSO cells) acts as a ligand for a receptor present on normal peripheral lymphocytes and induces apoptotic cell death. It is expressed in uterine and ovarian carcinomas, especially in invasive cancers. This immunohistochemical study is aimed to elucidate the expression of RCAS1 in human pituitary adenomas in order to clarify its role in their proliferative regulation and invasiveness. Five normal pituitary glands, 50 human pituitary adenomas, and one malignant glioma were subjected to immunohistochemical studies. In normal pituitary glands, immunostaining of RCAS1 and MIB-1 was not found. In malignant glioma, large numbers of cell nuclei were positive for MIB-1 (MIB-1 index: 28%), and RCAS1 was detected both in the cytoplasm and on the membrane of the tumor cells. Expression of RCAS1 was noted in 48% of pituitary adenomas immunohistochemically (60.0% of growth hormone-secreting adenomas, 60.0% of prolactin-secreting adenomas, 42.9% of adrenocorticotrophin-secreting adenomas, 40.0% of thyroid-stimulating hormone-secreting adenomas, 33.3% of nonfunctioning adenomas, and 44.4% of gonadotropin-subunit-positive adenomas). It showed no correlation with tumor type, size, and invasiveness. The statistically significant relationship between RCAS1 and MIB-1 positivity was identified in our study. These results suggest that expression of RCAS1 as well as MIB-1 positivity predict the growth potential of individual pituitary adenomas.
Insights
Receptor-binding cancer antigen expressed on SiSO cells (RCAS1) and MIB-1 positivity may predict pituitary adenoma growth potential. This study investigated RCAS1 expression in human pituitary adenomas, finding a significant relationship with MIB-1.
Area of Science:
- Endocrinology
- Oncology
- Immunohistochemistry
Background:
- Receptor-binding cancer antigen expressed on SiSO cells (RCAS1) is a ligand that induces apoptotic cell death and is found in uterine and ovarian carcinomas.
- RCAS1's role in pituitary adenomas, particularly in relation to proliferation and invasiveness, remains unclear.
Purpose of the Study:
- To investigate the expression of RCAS1 in human pituitary adenomas.
- To clarify the role of RCAS1 in the proliferative regulation and invasiveness of pituitary adenomas.
- To determine the correlation between RCAS1 expression and MIB-1 positivity.
Main Methods:
- Immunohistochemical analysis of RCAS1 and MIB-1 expression.
- Study included five normal pituitary glands, 50 human pituitary adenomas, and one malignant glioma.
- Analysis of RCAS1 expression across different pituitary adenoma subtypes.
Main Results:
- RCAS1 and MIB-1 were not detected in normal pituitary glands.
- RCAS1 was detected in 48% of pituitary adenomas, with varying rates across subtypes.
- A statistically significant relationship was found between RCAS1 and MIB-1 positivity.
- RCAS1 expression did not correlate with tumor type, size, or invasiveness.
Conclusions:
- RCAS1 expression, along with MIB-1 positivity, may serve as predictive markers for pituitary adenoma growth potential.
- Further research is warranted to fully elucidate RCAS1's role in pituitary tumorigenesis.